Akoya Biosciences Inc. Finalizes Merger with Quanterix, Terminates Key Agreements
Akoya Biosciences Inc. has completed its merger with Quanterix, converting each share of Akoya’s stock into 0.1461 shares of Quanterix and $0.38 in cash. The merger also involved the termination of several agreements, including the Equity Distribution Agreement with Piper Sandler & Co., and the repayment of obligations under its Credit Agreement with MidCap Financial Trust. This marks a significant milestone in the integration of the two companies.
Akoya Biosciences Inc. has announced the completion of its merger with Quanterix, following the terms of the Merger Agreement. At the effective time of the merger, each outstanding share of Akoya’s common stock was converted into the right to receive 0.1461 shares of Quanterix’s common stock and $0.38 in cash. As part of the merger, Akoya also terminated several agreements, including its Equity Distribution Agreement with Piper Sandler & Co., and repaid all outstanding obligations under its Credit Agreement with MidCap Financial Trust. This marks a significant milestone in the integration process between the two companies. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akoya Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-066306), on July 08, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
